Board Meeting Outcome
Board approves audited FY2025‑26 results; re-appoints MD Suresh K. Agrawal (subject to shareholders)
Board adopted audited standalone & consolidated financial statements and approved audited results for year ended 31 Mar 2026 with unmodified audit opinion; approved re-appointment of Mr Suresh K. Agrawal as MD for 3 years from 23 Nov 2026, subject to shareholder approval.



